- $849.87m
- $760.36m
- $14.08m
Moderna slides after judge sides with Arbutus in patent fight
Moderna shares fall after judge sides with Arbutus in patent fight
Arbutus Biopharma Corp reports results for the quarter ended in December - Earnings Summary
Arbutus Biopharma Corp expected to post a loss of 12 cents a share - Earnings Preview
Brief: Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Brief: Arbutus Reports Third Quarter 2023 Financial Results And Provides Corporate Update
Brief: Arbutus Biopharma Q3 Revenue USD 4.7 Million Vs. IBES Estimate USD 4.75 Million
Brief: Arbutus Announces CEO, William Collier, To Retire Dec. 31, 2023
Arbutus Biopharma Corp expected to post a loss of 11 cents a share - Earnings Preview
Brief: Arbutus Reports Second Quarter 2023 Financial Results And Corporate Update
Arbutus Biopharma Corp reports results for the quarter ended in June - Earnings Summary
Brief: Arbutus Biopharma Q2 Revenue USD 4.7 Million Vs. IBES Estimate USD 6.19 Million
Arbutus Biopharma Corp expected to post a loss of 11 cents a share - Earnings Preview
Brief: Arbutus Appoints Melissa V Rewolinski, PhD To Its Board Of Directors
Brief: Arbutus Biopharma Corp Board Increased Size Of Board By One Member
Brief: Arbutus Doses First Patient In Additional Treatment Arm Of Phase 2a Triple Combination Clinical Trial That Includes A PD-1 Monoclonal Antibody
Brief: Arbutus Presents Preliminary AB-729 And Pegylated Interferon Alfa-2A Combination Data At EASL Congress 2023
Arbutus Biopharma Corp reports results for the quarter ended in March - Earnings Summary
Brief: Arbutus Reports First Quarter 2023 Financial Results And Corporate Update